Literature DB >> 8931486

Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.

R A Newton1, S L Phipps, T P Flanigan, N R Newberry, J E Carey, C Kumar, B McDonald, C Chen, J M Elliott.   

Abstract

Stable transfection of the human neuroblastoma cell line SH-SY5Y with the human 5-hydroxytryptamine2A (5-HT2A) or 5-HT2C receptor cDNA produced cell lines demonstrating ligand affinities that correlated closely with those for the corresponding endogenous receptors in human frontal cortex and choroid plexus, respectively. Stimulation of the recombinant receptors by 5-HT induced phosphoinositide hydrolysis with higher potency but lower efficacy at the 5-HT2C receptor (pEC50 = 7.80 +/- 0.06) compared with the 5-HT2A receptor (pEC50 = 7.30 +/- 0.08). Activation of the 5-HT2A receptor caused a transient fourfold increase in intracellular Ca2+ concentration. Whole-cell recordings of cells clamped at -50 mV demonstrated a small inward current (2 pA) in response to 10 microM 5-HT for both receptors. There were no differences in potency or efficacy of phosphoinositide hydrolysis among four hallucinogenic [d-lysergic acid diethylamide (LSD), 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane (DOI), 5-methoxy-N,N-dimethyltryptamine, and mescaline] and three nonhallucinogenic drugs (m-chlorophenylpiperazine, quipazine, and ergotamine). Comparison of equipotent doses producing 20% of the maximal response induced by 5-HT revealed selective activation of the 5-HT2A receptor by LSD and to a lesser degree by DOI, mescaline, and ergotamine. Quipazine and 5-methoxy-N,N-dimethyltryptamine were relatively nonselective, whereas m-chlorophenylpiperazine selectively activated the 5-HT2C receptor. It is unlikely therefore that hallucinosis is mediated primarily by activity at the 5-HT2C receptor, whereas activity at the 5-HT2A receptor may represent an important but not unique mechanism associated with hallucinogenic drug action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931486     DOI: 10.1046/j.1471-4159.1996.67062521.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.

Authors:  R H Porter; K R Benwell; H Lamb; C S Malcolm; N H Allen; D F Revell; D R Adams; M J Sheardown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

3.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

Review 4.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Neuropharmacology       Date:  2011-01-20       Impact factor: 5.250

5.  Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.

Authors:  Michael A Benneyworth; Randy L Smith; Robert J Barrett; Elaine Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  2005-01-12       Impact factor: 4.530

6.  Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors.

Authors:  Claudio Acuña-Castillo; Claudio Villalobos; Pablo R Moya; Patricio Sáez; Bruce K Cassels; J Pablo Huidobro-Toro
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

7.  A unique phenotype of 5-HT2C, agonist-induced GTPgamma35S binding, transferable to 5-HT2A and 5-HT2B, upon swapping intracellular regions.

Authors:  Glen L Alberts; Christopher L Chio; Wha Bin Im; Jerry L Slightom
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 8.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 9.  3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.

Authors:  Raúl López-Arnau; Jordi Camarasa; Marcel Lí Carbó; Núria Nadal-Gratacós; Pol Puigseslloses; María Espinosa-Velasco; Edurne Urquizu; Elena Escubedo; David Pubill
Journal:  Front Psychiatry       Date:  2022-10-03       Impact factor: 5.435

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.